GT Biopharma, Inc. Stock News

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could

GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's

BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pr

BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-sp

BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprie

GT Biopharma (GTBP), a clinical-stage immunooncology company, has named Manu Ohri as its Chief Financial Officer ((CFO)) with immediate effect.Ohri has over 25 years of management,…

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprie

State Street Corp acquired a new position in shares of GT Biopharma, Inc. (OTCMKTS:GTBP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 374,704 shares of the company’s stock, valued at approximately $5,808,000. State Street Corp owned about 1.77% of GT Biopharma at […]

BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company''s proprietary natural killer (NK) cell

Zacks Investment Research downgraded shares of GT Biopharma (OTCMKTS:GTBP) from a hold rating to a sell rating in a research report report published on Monday, Zacks.com reports. According to Zacks, “GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and […]

Zacks Investment Research cut shares of GT Biopharma (OTCMKTS:GTBP) from a buy rating to a hold rating in a report published on Tuesday, Zacks.com reports. According to Zacks, GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet []

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

Vanguard Group Inc. increased its holdings in shares of GT Biopharma, Inc. (OTCMKTS:GTBP) by 267.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 982,269 shares of the companys stock after acquiring an additional 714,605 shares during the quarter. Vanguard Group Inc.s holdings in GT Biopharma were worth $15,225,000 as of its most recent filing []